RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin

Molecular Pharmacology

Volumn 68, Issue 5, 2005, Pages 1311-1319

  Putral, Lisa N ^a   Bywater, Megan J ^a   Gu, Wenyi ^a   Saunders, Nicholas A ^a   Gabrielli, Brian G ^a   Leggatt, Graham R ^a   McMillan, Nigel A J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; LENTIVIRUS VECTOR; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E6; TRANSCRIPTION FACTOR E7; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL AGING; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UTERINE CERVIX CANCER; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS ONCOGENE; WART VIRUS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 27544455180     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.014191     Document Type: Article

References (40)

1. Boyer SN, Wazer DE, and Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624.
2. Brown JM and Wouters BG (1999) Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391-1399.
3. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, and Hoppe-Seyler F (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22:5938-5945.
4. Choo KB, Pan CC, and Han SH (1987) Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161:259-261.
5. Cote RJ, Esrig D, Groshen S, Jones PA, and Skinner DG (1997) p53 and treatment of bladder cancer. Nature (Lond) 385:123-125.
6. Decatris MP, Sundar S, and O'Byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 30:53-81.
7. DeFilippis RA, Goodwin EC, Wu L, and DiMaio D (2003) Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 77:1551-1563.
8. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92:9363-9367.
9. Doorbar J, Parton A, Hartley K, Banks L, Crook T, Stanley M, and Crawford L (1990) Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 178:254-262.
10. Ferlay J, Bray FP, Pisani P, and Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon, France.
11. Gagnon V, Mathieu I, Sexton E, Leblanc K, and Asselin E (2004) AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94:785-795.
12. Gonzalez VM, Fuertes MA, Alonso C, and Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657-663.
13. Goodwin EC, Yang E, Lee CJ, Lee HW, DiMaio D, and Hwang ES (2000) Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci USA 97:10978-10983.
14. Hall AH and Alexander KA (2003) RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 77:6066-6069.
15. Horner SM, DeFilippis RA, Manuelidis L, and DiMaio D (2004) Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase- independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 78:4063-4073.
16. Howley PM (1996) Papillomaviridae: the viruses and their replication. In Fields' Virology (Fields BN, Knipe DM, and Howley PM eds), 3rd ed, vol. 2, pp. 2045-2076, Lippincott-Raven, Philadelphia.
17. Jiang M and Milner J (2002) Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21:6041-6048.
18. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, Takahashi M, Nakamura T, Sato K, and Terakawa N (1998) A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 34:1802-1806.
19. Koivusalo R, Krausz E, Helenius H, and Hietanen S (2005) Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68:372-382.
20. Loizzi V, Cormio G, Loverro G, Selvaggi L, Disaia PJ, and Cappuccini F (2003) Chemoradiation: a new approach for the treatment of cervical cancer. Int J Gynecol Cancer 13:580-586.
21. Makris A, Powles TJ, Dowsett M, and Allred C (1995) p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345:1181-1182.
22. Mathieu MC, Koscielny S, Le Bihan ML, Spielmann M, and Arriagada R (1995) p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group. Lancet 345:118219.
23. Pestell KE, Hobbs SM, Titley JC, Kelland LR, and Walton MI (2000) Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57:503-511.
24. Pirollo KF, Bouker KB, and Chang EH (2000) Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-432.
25. Psyrri A, DeFilippis RA, Edwards AP, Yates KE, Manuelidis L, and DiMaio D (2004) Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res 64:3079-3086.
26. Romanczuk H and Howley PM (1992) Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA 89:3159-3163.
27. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401-406.
28. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
29. Sherman L and Alloul N (1992) Human papillomavirus type 16 expresses a variety of alternatively spliced mRNAs putatively encoding the E2 protein. Virology 191:953-959.
30. Siddik ZH (2002) Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 112:263-284.
31. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
32. Smotkin D, Prokoph H, and Wettstein FO (1989) Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 63:1441-1447.
33. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM, and Arrand JR (1995) Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J Virol 69:7023-7031.
34. Taniguchi A and Yasumoto S (1990) A major transcript of human papillomavirus type 16 in transformed NIH 3T3 cells contains polycistronic mRNA encoding E7, E5 and E1-E4 fusion gene. Virus Genes 3:221-233.
35. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, and Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64:356-362.
36. Wacheck V, Losert D, Gunsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Muller M, and Jansen B (2003) Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 13:393-400.
37. Weller M (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292:435-445.
38. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, and Yamato K (2003) In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 8:762-768.
39. Zhang M, Zhang X, Bai CX, Chen J, and Wei MQ (2004) Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 25:61-67.
40. Zur Hausen H (1994) Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 186:131-156.